Evaluación de actividad física como coadyuvante terapéutico para pacientes con enfermedad inflamatoria intestinal: una revisión.
Evaluation of physical activity as a therapeutic adjuvant for patients with inflammatory bowel disease: A systematic review.
Keywords:
physical activity, inflammatory bowel disease, therapeutic adjuvant, fatigue, biomarkers, quality of life
Abstract
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). Pharmacological treatment in IBD presents a loss of efficacy and side effects, inviting to consider alternative strategies, such as the practice of physical activity (PA), as a therapeutic adjuvant. The purpose of this review was to evaluate the effectiveness of PA interventions as a tool to increase physical fitness, and health-related quality of life (HRQoL) and improve the symptomatology in patients with CD and UC, identifying the optimal PA component. The review was performed, by searching the electronic databases Medline (PubMed), SciELO, and Cochrane Library Plus, including randomized controlled trials from the last 10 years that related to IBD and PA, until January 31, 2022. We found four studies with a total of 133 patients. The performance of PA in patients with IBD (UC and CD) increases (p>0.05) physical capacity, skeletal muscle mass, bone mineral density, and HRQoL, significantly (p<0.05) increasing mood. In addition, it significantly (p<0.05) decreases intestinal inflammation and extraintestinal manifestations. A trend of reduction (p>0.05) of fatigue, blood pressure, and microbiota restoration was observed. Moderate PA and performed regularly for a minimum of eight weeks, favors the improvement of the IBD patient at the physical, psychological, HRQoL, and symptomatology levels.
Downloads
Download data is not yet available.
References
Oviedo C, Yañez M, Pennacchiotti V. Frequency of oral manifestation in patients with inflammatory bowel disease in Chile. Int J Odontostomatol 2017; 11: 267–271. Disponible en: https:// www.scielo.cl/scielo.php?script=sci_ abstract&pid=S0718-381X2017000300 267&lng=en&nrm=iso#:~:text=Of%20 these% 20patients%2C%2037%2 0%25%20 presented,recurrent%20oral%20ulcer%20 (ROU).
Meligrana N, Quera R, Figueroa C, Ibáñez P, Lubascher J, Kronberg U. Factores ambientales en el desarrollo y evolución de la enfermedad inflamatoria intestinal. Rev Med Chile 2019; 147: 212–220. Disponible en: https://www. scielo.cl/scielo.php?pid=S0034-9887 2019000200212&script =sci_artt ext&tlng=en
World Gastroenterology Organization (WGO). Practice Guideline Inflammatory bowel disease (IBD). World Gastroenterology Organisation [Internet] 2022 [citado, 2022 febrero 10] Disponible en: https:// www.worldgastroenterology.org/guideli- nes/global-guidelines/inflammatory-bowel- disease-ibd.
Yamamoto-Furusho JK, Bosques-Padilla FJ, Charúa-Guindic L, Cortés-Espinosa T, Miranda-Cordero RM, Saez A, Ledesma I. Inflammatory bowel disease in Mexico: epidemiology, burden of disease, and treatment trends. Rev Gastroenterol México 2020; 85: 246–256. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32143974/.
The European Federation of Crohn’s & ulcerative colitis associations (EFCCA). What is inflammatory bowel disease? European Federation of Crohn’s & ulcerative colitis associations 2022 [Internet] [citado, 2022 febrero 10] Disponible en: https:// www.efcca.org/en/what-ibd.
Ng S, Shi H, Hamidi N, Underwood F, Tang W, Benchimol E. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/29050646/.
Puig L, Ruiz De Morales J, Dauden E, Andreu J, Cervera R. La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en España. Rev Esp Salud Públi- ca 2019; 93: 1–14. Disponible en: https:// scielo.isciii.es/scielo.php?script=sci_abstr act&pid=S1135-57272019000100069.
Velásquez JR. Enfermedad de Crohn. Enfoque diagnóstico y terapéutico de las primeras visitas. Rev Colomb Gastroenterol 2014; 29: 404–416. Disponible en: https://revis- tagastrocol.com/index.php/rcg/article/ view/438.
Büsch K, Sonnenberg A, Bansback N. Impact of inflammatory bowel disease on disability. Curr Gastroenterol Rep 2014; 16: 414. Disponible en: https://pubmed.ncbi. nlm.nih.gov/25231757/.
Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019; 12: 113–122. Disponible en: https://pubmed.ncbi.nlm.nih. gov/31406511/.
Ponferrada A. Efectos adversos de fármacos en EII Efectos adversos de fármacos. 2015. Grupo Español de Trabajo en Enfermería de Crohn y Colitis
Ulcerosa [Internet] 2015 Disponible en: https://geteccu.org/pacien- tes/efectos-adversos-de-farmacos-en-eii.
Fernández-Lázaro D, Mielgo-Ayuso J, Caballero-García A, Córdova-Martínez A, Lázaro MP, Fernández-Lázaro CI. Physical activity in oncological breast cancer patients: non-pharmacological sports medical therapy? Systematic review. Arch med Deport 2020; 198: 266–274. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=7660871.
Fernández-Lázaro D, Mielgo-Ayuso J, Lázaro-Asensio MP, Martínez AC, Caballero-García A, Fernández-Lázaro CI. Intradialytic physical exercise in chronic kidney disease: A systematic review of health outcomes. Arch Med Deport 2020; 37: 419–429. Disponible en: https://dialnet.unirio- ja.es/servlet/articulo?codigo=7772527
Ramírez-Véleza R. Physical activity and health-related quality of life: a systematic review of current evidence. Rev Andal Med Deport 2010. 3: 110-120 Disponible en: https://www.elsevier.es/es-revista-revista-andaluza-medicina-del-deporte-284-articu-lo-actividad-fisica-calidad-vida-relacionada- X1888754610543999.
Llopis PQ, García-Galbis M. Control glucémico a través del ejercicio físico en pacientes con diabetes mellitus tipo 2; revisión sistemática. Nutr Hosp 2015; 31: 1465–1472. Disponible en: https:// www.mendeley.com/catalogue/0b1fc2f8- 388f-3490-9119-9be525e2b952/?utm_source=desktop&utm_medium=1.19.8&utm_campaign=op en_catalog&u ser D ocumen t Id=%7Be86582ab-f1cc- 325e-9458- cc6941414b32%7D.
Defilippis E, Tabani S, Warren R, Christos P, Bosworth B, Scherl E. Exercise and self-reported limitations in patients with inflammatory bowel disease. Dig Dis Sci 2016; 61: 215–220. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/26254773/
Cordero A, Masiá MD, Galve E. Ejercicio físico y salud. Rev Esp Cardiol 2014; 67: 748–753. Disponible en: http://www. revespcardiol.org/es-ejercicio-fisico-salud- articulo-S0300893214002656.
Candón-Liñán Á, Sánchez-Olliver AJ, Galancho-Reina I, Suárez-Carmona W, González JA. Ejercicio físico, obesidad e inflamación. EmásF, revista digital de educación física 2016; 41: 65-82. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=5558014.
Narula N, Fedorak R. Exercise and inflammatory bowel disease. Can J Gastroenterol 2008; 22: 497-504. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/18478136/.
Reboredo M, Pinheiro B, Chebli J. Physical exercise programmes in patients with inflammatory bowel disease. J Crohns coli- tits 2017; 11: 1286. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/28369347/.
Bilski J, Brzozowski B, Mazur A, Sliwowski Z, Brzozowski T. The role of physical exercise in inflammatory bowel disease. Biomed Res Int 2014; 2014: 429031. Disponible en: https://pubmed.ncbi.nlm.nih. gov/24877092/.
Cronin O, Barton W, Moran C, Sheehan D, Whiston R, Nugent H, Mccarthy Y, Molloy C, O’sullivan O, Cotter PD, Molloy MG, Shanahan F. Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent inflammatory bowel disease: a randomized controlled cross-over trial. BMC Gastroenterol 2019; 19: 29. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 30755154/.
Tew GA, Leighton D, Carpenter R, Anderson S, Langmead L, Ramage J, Faulkner J, Coleman E, Fairhurst C, Seed M, Bottoms L. High-intensity interval training and moderate-intensity continuous training in adults with Crohn’s disease: a pilot rando- mised controlled trial. BMC Gastroenterol 2019; 19: 1–11. Disponible en: https://pub- med.ncbi.nlm.nih.gov/30696423/.
Klare P, Nigg J, Nold J, Haller B, Krug A, Mair S, Thoeringer CK, Christle JW, Schmid RM, Halle M, Hubber W. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. Digestion 2015; 91: 239–247. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/25823689/.
Jones K, Baker K, Speight R, Thompson N, Tew G. Randomised clinical trial: combined impact and resistance training in adults with stable Crohn’s disease. Aliment Pharmacol Ther 2020; 52: 964–975. Disponible en: https://pubmed.ncbi.nlm.nih. gov/33119156/.
D’haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, AerdenI, Van Assche G, Olmen GV, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2218–2224. Disponible en: https://pub- med.ncbi.nlm.nih.gov/22344983/.
Engels M, Cross R, Long M. Exercise in patients with inflammatory bowel diseases: current perspectives. Clin Exp Gastroenterol 2017; 11: 1–11. Disponible en: https://pubmed.ncbi.nlm.nih. gov/29317842/.
Eckert KG, Abbasi-Neureither I, Köppel M, Huber G. Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications. BMC Gastroenterol 2019; 19: 115. Disponible en: https://pubmed.ncbi.nlm. nih.gov/31266461/.
Fernández-Lázaro D, Díaz J, Caballero A, Córdova A. The training of strength-resistance in hypoxia: effect on muscle hypertrophy. Rev Biomed 2019; 39: 212–220. Disponible en: https://pubmed.ncbi.nlm.nih. gov/31021559/.
Papadimitriou K. Effect of resistance exercise training on Crohn’s disease patients. Intest Res 2020; 19: 275–281. Disponible en: http://www.irjournal.org/journal/view. php?number=892.
Holik D, Včev A, Milostić-Srb A, Salinger Ž, Ivanišević Z, Včev I, Miškulin M. The effect of daily physical activity on the activity of inflammatory bowel diseases in therapy-free patients. Acta Clin Croat 2019; 58: 202-212. Disponible en: https://pubmed. ncbi.nlm.nih.gov/31819315/.
Manonelles P, De Teresa C, Alacid F, Álvarez J, Del Valle M, Gaztañaga T, Gondra J, Luengo E, Martínez P, Gil N. Deporte recreacional saludable. Documento de consenso de la sociedad española de medicina del deporte (SEMED-FEMEDE). Arch Med del Deport 2016; 33: 8–41. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=6273644.
González-Gross M, Gutiérrez A, Mesa JL, Ruiz-Ruiz J, Castillo MJ. La nutrición en la práctica deportiva: Adaptación de la pirámide nutricional a las características de la dieta del deportista. Arch Latinoam Nutr 2001; 51: 321–331. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0004-06222001000400001.
De la Morena F, Gisbert JP. Anemia y enfermedad inflamatoria intestinal. Rev Esp Enferm Dig. 2008; 100: 285-293. Disponible en: https://scielo.isciii. es/scielo.php?script=sci_arttext&pid=S1130-01082008000500007.
Marins JCB, Marins NM, Fernández M. Aplicaciones de la frecuencia cardiaca máxima en la evaluación y prescripción de ejercicio. Apunt Med l’Esport. 2010; 45: 251–258. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=3664676.
Bernal-Reyes F, Peralta-Mendívil A, Gavotto-Nogales HH, Placencia-Camacho L. Principios de entrenamiento deportivo para la mejora de las capacidades físicas. Biotecnia 2014; 16: 42-49. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=7930481.
López-Sendón J, López E. Reducción de la frecuencia cardiaca. Otras oportunidades terapéuticas. Rev Española Cardiol 2007; 7: 53-57. Disponible en: http://www. revespcardiol.org/es-reduccion-frecuen- cia-cardiaca-otras-oportunidades-articulo- S113135870775776X.
Vogelaar L, Spijker A, Van der Woude C. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101-109. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/21694833/.
Chavarria-Herbozo CM. Prevalencia y factores asociados a la fatiga en pacientes con enfermedad inflamatoria intestinal. [Tesis doctoral] Madrid: Univ. Autónoma de Madrid; 2018. Disponible en: https://dialnet. unirioja.es/servlet /tesis?codigo=150883.
D’Silva A, Fox DE, Nasser Y, Vallance JK, Quinn RR, Ronksley PE. Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: a systematic review with meta-analysis. Clin Gastroenterol Hepatol. 2021; 20: 995-1009.e7. Disponible en: https://pubmed.ncbi.nlm.nih. gov/34216824/.
Benítez EM. Protocolos diagnóstico-terapéuticos de gastroenterología, hepatología y nutrición pediátrica SEGHNP-AEP. Ergón. 2010; 1: 157-269. Disponible en: https:// www.seghnp.org/documentos/protocolos- diagnostico-terapeuticos-de-gastroentero- logia-hepatologia-y-nutricion.
Quiroz-Mora CA, Serrato-Ramírez DM, Bergonzoli-Peláez G. Factores asociados con la adherencia a la actividad física en pacientes con enfermedades crónicas no transmisibles. Rev Salud Pública 2018; 20: 460–464. Disponible en: https://doi. org/10.15446/rsap.V20n4.629597.
Ortiz-Alvarez L, Xu H, Martinez-Tellez B. Influence of exercise on the human gut microbiota of healthy adults: a systematic review. Clin Transl Gastroenterol 2020; 11: e00126. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32463624/.
Rozich J, Dulai P, Fumery M, Sandborn W, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2020; 18: 2437-2447. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32142940/.
Taylor K, Scruggs P, Balemba O, Wiest M, Vella C. Associations between physical activity, resilience, and quality of life in people with inflammatory bowel disease. Eur J Appl Physiol 2018; 118: 829–836. Disponible en: https://pubmed.ncbi.nlm.nih. gov/29411129/.
Estay C, Simian D, Escaffi MJ, Figueroa C, Ibáñez P, Lubascher J, Kronberg U, Flores L, Quera R. Obesidad y enfermedad inflamatoria intestinal. Gastroenterol. latinoam 2017; 28: 177-184. Disponible en: http:// gastrolat.org/DOI/PDF/10.0716/gastro- lat2017n3000.04.pdf
Vavricka S, Schoepfer A, Scharl M, Lakatos P, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015; 21: 1982– 1992. Disponible en: https://pubmed.ncbi. nlm.nih.gov/26154136/.
Cano S, Rubio C, Fernández R, Centeno O, Daniel C. Metabolismo mineral óseo en la enfermedad inflamatoria intestinal. Rev Osteoporos Metab Min. 2009; 1: 21–28. Disponible en: https://www.redalyc.org/pdf
/3609/360933648004.pdf.
Bird SP, Tarpenning KM, Marino FE. De-signing resistance training programmes to enhance muscular fitness: a review of the acute programme variables. Sports Med 2005; 35: 841-851. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/16180944/.
Pedersen B, Febbraio M. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457–465. Disponible en: https://pubmed.ncbi. nlm.nih.gov/22473333/.
Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology. Bethesda 2008; 23: 160–170. Disponible en: https://pub- med.ncbi.nlm.nih.gov/18556469/.
Mounier R, Lantier L, Leclerc J, Sotiro-poulos A, Foretz M, Viollet B. Antagonistic control of muscle cell size by AMPK and mTORC1. Cell Cycle 2011; 10: 2640–2646. Disponible en: https://pubmed.ncbi.nlm. nih.gov/21799304/.
Pérez R, Carlos J. Interleukin-10 and Coronary Disease. Rev Española Cardiol 2012; 55: 738-750. Disponible en: https://www. sciencedirect.com/science/article/abs/ pii/S0300893202766931.
Beery RM, Li E, Fishman LN. Impact of pediatric inflammatory bowel disease diagnosis on exercise and sports participation: Patient and parent perspectives. World J Gastroenterol 2019; 25; 4493-4501. Disponible en: https://pubmed.ncbi.nlm.nih. gov/31496627/.
Escribano LI, Rodríguez AS, Centeno G. Etiopathogenic diagnosis protocol of chronic diarrhea. Medicine 2020; 13: 38–44. Disponible en: https://www.medicineonli- ne.es/es-protocolo- diagnostico-etiopatoge- nico-diarrea-cronica-articulo-S0304541220 300056?referer=seccion.
Salvo-Romero E, Alonso-Cotoner C, Pardo-Camacho C, Casado-Bedmar M, Vicario M. Función barrera intestinal y su implicación en enfermedades digestivas. Rev Esp Enferm Dig 2015; 107: 686-696. Disponible en: https://scielo.isciii.es/pdf/diges/ v107n11/es_revision.pdf.
Álvarez J, Fernández-Real JM, Guarner F, Gueimonde M, Rodríguez JM, Saenz M. Gut microbes and health 2021; 44: 519–535. Disponible en: https://www. sciencedirect.com/science/article/pii/ S0210570521000583.
Cronin O, Barton W, Skuse P, Penney N, Garcia-Pérez I, Murphy E. A Prospective metagenomic and metabolomic analysis of the impact of exercise and/or whey protein supplementation on the gut microbiome of sedentary adults. MSystems 2018; 3: 18-44. Disponible en: https://pubmed.ncbi.nlm. nih.gov/29719871/.
Barton W, Penney N, Cronin O, Garcia-Pérez I, Molloy M, Holmes E. The micro-biome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut 2018; 67: 625–633. Disponible en: https://pubmed.ncbi.nlm.nih. gov/28360096/.
Petersen LM, Bautista EJ, Nguyen H, Hanson BM, Chen L, Lek SH. Community characteristics of the gut microbiomes of competitive cyclists. Microbiome 2017; 51: 1–13. Disponible en: https://micro- biomejournal.biomedcentral.com/arti- cles/10.1186/s40168-017-0320-47.
Colmenarez G, Armania E. Calidad de vida en pacientes con enfermedad inflamatoria intestinal. Bol Med Postgrado 2018; 34: 17-23. Disponible en: https://revistas.uclave. org/ index.php/bmp/article/view/2526.
Meligrana N, Quera R, Figueroa C, Ibáñez P, Lubascher J, Kronberg U. Factores ambientales en el desarrollo y evolución de la enfermedad inflamatoria intestinal. Rev Med Chile 2019; 147: 212–220. Disponible en: https://www. scielo.cl/scielo.php?pid=S0034-9887 2019000200212&script =sci_artt ext&tlng=en
World Gastroenterology Organization (WGO). Practice Guideline Inflammatory bowel disease (IBD). World Gastroenterology Organisation [Internet] 2022 [citado, 2022 febrero 10] Disponible en: https:// www.worldgastroenterology.org/guideli- nes/global-guidelines/inflammatory-bowel- disease-ibd.
Yamamoto-Furusho JK, Bosques-Padilla FJ, Charúa-Guindic L, Cortés-Espinosa T, Miranda-Cordero RM, Saez A, Ledesma I. Inflammatory bowel disease in Mexico: epidemiology, burden of disease, and treatment trends. Rev Gastroenterol México 2020; 85: 246–256. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32143974/.
The European Federation of Crohn’s & ulcerative colitis associations (EFCCA). What is inflammatory bowel disease? European Federation of Crohn’s & ulcerative colitis associations 2022 [Internet] [citado, 2022 febrero 10] Disponible en: https:// www.efcca.org/en/what-ibd.
Ng S, Shi H, Hamidi N, Underwood F, Tang W, Benchimol E. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/29050646/.
Puig L, Ruiz De Morales J, Dauden E, Andreu J, Cervera R. La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en España. Rev Esp Salud Públi- ca 2019; 93: 1–14. Disponible en: https:// scielo.isciii.es/scielo.php?script=sci_abstr act&pid=S1135-57272019000100069.
Velásquez JR. Enfermedad de Crohn. Enfoque diagnóstico y terapéutico de las primeras visitas. Rev Colomb Gastroenterol 2014; 29: 404–416. Disponible en: https://revis- tagastrocol.com/index.php/rcg/article/ view/438.
Büsch K, Sonnenberg A, Bansback N. Impact of inflammatory bowel disease on disability. Curr Gastroenterol Rep 2014; 16: 414. Disponible en: https://pubmed.ncbi. nlm.nih.gov/25231757/.
Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019; 12: 113–122. Disponible en: https://pubmed.ncbi.nlm.nih. gov/31406511/.
Ponferrada A. Efectos adversos de fármacos en EII Efectos adversos de fármacos. 2015. Grupo Español de Trabajo en Enfermería de Crohn y Colitis
Ulcerosa [Internet] 2015 Disponible en: https://geteccu.org/pacien- tes/efectos-adversos-de-farmacos-en-eii.
Fernández-Lázaro D, Mielgo-Ayuso J, Caballero-García A, Córdova-Martínez A, Lázaro MP, Fernández-Lázaro CI. Physical activity in oncological breast cancer patients: non-pharmacological sports medical therapy? Systematic review. Arch med Deport 2020; 198: 266–274. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=7660871.
Fernández-Lázaro D, Mielgo-Ayuso J, Lázaro-Asensio MP, Martínez AC, Caballero-García A, Fernández-Lázaro CI. Intradialytic physical exercise in chronic kidney disease: A systematic review of health outcomes. Arch Med Deport 2020; 37: 419–429. Disponible en: https://dialnet.unirio- ja.es/servlet/articulo?codigo=7772527
Ramírez-Véleza R. Physical activity and health-related quality of life: a systematic review of current evidence. Rev Andal Med Deport 2010. 3: 110-120 Disponible en: https://www.elsevier.es/es-revista-revista-andaluza-medicina-del-deporte-284-articu-lo-actividad-fisica-calidad-vida-relacionada- X1888754610543999.
Llopis PQ, García-Galbis M. Control glucémico a través del ejercicio físico en pacientes con diabetes mellitus tipo 2; revisión sistemática. Nutr Hosp 2015; 31: 1465–1472. Disponible en: https:// www.mendeley.com/catalogue/0b1fc2f8- 388f-3490-9119-9be525e2b952/?utm_source=desktop&utm_medium=1.19.8&utm_campaign=op en_catalog&u ser D ocumen t Id=%7Be86582ab-f1cc- 325e-9458- cc6941414b32%7D.
Defilippis E, Tabani S, Warren R, Christos P, Bosworth B, Scherl E. Exercise and self-reported limitations in patients with inflammatory bowel disease. Dig Dis Sci 2016; 61: 215–220. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/26254773/
Cordero A, Masiá MD, Galve E. Ejercicio físico y salud. Rev Esp Cardiol 2014; 67: 748–753. Disponible en: http://www. revespcardiol.org/es-ejercicio-fisico-salud- articulo-S0300893214002656.
Candón-Liñán Á, Sánchez-Olliver AJ, Galancho-Reina I, Suárez-Carmona W, González JA. Ejercicio físico, obesidad e inflamación. EmásF, revista digital de educación física 2016; 41: 65-82. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=5558014.
Narula N, Fedorak R. Exercise and inflammatory bowel disease. Can J Gastroenterol 2008; 22: 497-504. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/18478136/.
Reboredo M, Pinheiro B, Chebli J. Physical exercise programmes in patients with inflammatory bowel disease. J Crohns coli- tits 2017; 11: 1286. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/28369347/.
Bilski J, Brzozowski B, Mazur A, Sliwowski Z, Brzozowski T. The role of physical exercise in inflammatory bowel disease. Biomed Res Int 2014; 2014: 429031. Disponible en: https://pubmed.ncbi.nlm.nih. gov/24877092/.
Cronin O, Barton W, Moran C, Sheehan D, Whiston R, Nugent H, Mccarthy Y, Molloy C, O’sullivan O, Cotter PD, Molloy MG, Shanahan F. Moderate-intensity aerobic and resistance exercise is safe and favorably influences body composition in patients with quiescent inflammatory bowel disease: a randomized controlled cross-over trial. BMC Gastroenterol 2019; 19: 29. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 30755154/.
Tew GA, Leighton D, Carpenter R, Anderson S, Langmead L, Ramage J, Faulkner J, Coleman E, Fairhurst C, Seed M, Bottoms L. High-intensity interval training and moderate-intensity continuous training in adults with Crohn’s disease: a pilot rando- mised controlled trial. BMC Gastroenterol 2019; 19: 1–11. Disponible en: https://pub- med.ncbi.nlm.nih.gov/30696423/.
Klare P, Nigg J, Nold J, Haller B, Krug A, Mair S, Thoeringer CK, Christle JW, Schmid RM, Halle M, Hubber W. The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. Digestion 2015; 91: 239–247. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/25823689/.
Jones K, Baker K, Speight R, Thompson N, Tew G. Randomised clinical trial: combined impact and resistance training in adults with stable Crohn’s disease. Aliment Pharmacol Ther 2020; 52: 964–975. Disponible en: https://pubmed.ncbi.nlm.nih. gov/33119156/.
D’haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, AerdenI, Van Assche G, Olmen GV, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2218–2224. Disponible en: https://pub- med.ncbi.nlm.nih.gov/22344983/.
Engels M, Cross R, Long M. Exercise in patients with inflammatory bowel diseases: current perspectives. Clin Exp Gastroenterol 2017; 11: 1–11. Disponible en: https://pubmed.ncbi.nlm.nih. gov/29317842/.
Eckert KG, Abbasi-Neureither I, Köppel M, Huber G. Structured physical activity interventions as a complementary therapy for patients with inflammatory bowel disease – a scoping review and practical implications. BMC Gastroenterol 2019; 19: 115. Disponible en: https://pubmed.ncbi.nlm. nih.gov/31266461/.
Fernández-Lázaro D, Díaz J, Caballero A, Córdova A. The training of strength-resistance in hypoxia: effect on muscle hypertrophy. Rev Biomed 2019; 39: 212–220. Disponible en: https://pubmed.ncbi.nlm.nih. gov/31021559/.
Papadimitriou K. Effect of resistance exercise training on Crohn’s disease patients. Intest Res 2020; 19: 275–281. Disponible en: http://www.irjournal.org/journal/view. php?number=892.
Holik D, Včev A, Milostić-Srb A, Salinger Ž, Ivanišević Z, Včev I, Miškulin M. The effect of daily physical activity on the activity of inflammatory bowel diseases in therapy-free patients. Acta Clin Croat 2019; 58: 202-212. Disponible en: https://pubmed. ncbi.nlm.nih.gov/31819315/.
Manonelles P, De Teresa C, Alacid F, Álvarez J, Del Valle M, Gaztañaga T, Gondra J, Luengo E, Martínez P, Gil N. Deporte recreacional saludable. Documento de consenso de la sociedad española de medicina del deporte (SEMED-FEMEDE). Arch Med del Deport 2016; 33: 8–41. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=6273644.
González-Gross M, Gutiérrez A, Mesa JL, Ruiz-Ruiz J, Castillo MJ. La nutrición en la práctica deportiva: Adaptación de la pirámide nutricional a las características de la dieta del deportista. Arch Latinoam Nutr 2001; 51: 321–331. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0004-06222001000400001.
De la Morena F, Gisbert JP. Anemia y enfermedad inflamatoria intestinal. Rev Esp Enferm Dig. 2008; 100: 285-293. Disponible en: https://scielo.isciii. es/scielo.php?script=sci_arttext&pid=S1130-01082008000500007.
Marins JCB, Marins NM, Fernández M. Aplicaciones de la frecuencia cardiaca máxima en la evaluación y prescripción de ejercicio. Apunt Med l’Esport. 2010; 45: 251–258. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=3664676.
Bernal-Reyes F, Peralta-Mendívil A, Gavotto-Nogales HH, Placencia-Camacho L. Principios de entrenamiento deportivo para la mejora de las capacidades físicas. Biotecnia 2014; 16: 42-49. Disponible en: https://dialnet.unirioja.es/servlet/ articulo?codigo=7930481.
López-Sendón J, López E. Reducción de la frecuencia cardiaca. Otras oportunidades terapéuticas. Rev Española Cardiol 2007; 7: 53-57. Disponible en: http://www. revespcardiol.org/es-reduccion-frecuen- cia-cardiaca-otras-oportunidades-articulo- S113135870775776X.
Vogelaar L, Spijker A, Van der Woude C. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101-109. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/21694833/.
Chavarria-Herbozo CM. Prevalencia y factores asociados a la fatiga en pacientes con enfermedad inflamatoria intestinal. [Tesis doctoral] Madrid: Univ. Autónoma de Madrid; 2018. Disponible en: https://dialnet. unirioja.es/servlet /tesis?codigo=150883.
D’Silva A, Fox DE, Nasser Y, Vallance JK, Quinn RR, Ronksley PE. Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: a systematic review with meta-analysis. Clin Gastroenterol Hepatol. 2021; 20: 995-1009.e7. Disponible en: https://pubmed.ncbi.nlm.nih. gov/34216824/.
Benítez EM. Protocolos diagnóstico-terapéuticos de gastroenterología, hepatología y nutrición pediátrica SEGHNP-AEP. Ergón. 2010; 1: 157-269. Disponible en: https:// www.seghnp.org/documentos/protocolos- diagnostico-terapeuticos-de-gastroentero- logia-hepatologia-y-nutricion.
Quiroz-Mora CA, Serrato-Ramírez DM, Bergonzoli-Peláez G. Factores asociados con la adherencia a la actividad física en pacientes con enfermedades crónicas no transmisibles. Rev Salud Pública 2018; 20: 460–464. Disponible en: https://doi. org/10.15446/rsap.V20n4.629597.
Ortiz-Alvarez L, Xu H, Martinez-Tellez B. Influence of exercise on the human gut microbiota of healthy adults: a systematic review. Clin Transl Gastroenterol 2020; 11: e00126. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32463624/.
Rozich J, Dulai P, Fumery M, Sandborn W, Singh S. Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2020; 18: 2437-2447. Disponible en: https://pubmed. ncbi.nlm.nih.gov/32142940/.
Taylor K, Scruggs P, Balemba O, Wiest M, Vella C. Associations between physical activity, resilience, and quality of life in people with inflammatory bowel disease. Eur J Appl Physiol 2018; 118: 829–836. Disponible en: https://pubmed.ncbi.nlm.nih. gov/29411129/.
Estay C, Simian D, Escaffi MJ, Figueroa C, Ibáñez P, Lubascher J, Kronberg U, Flores L, Quera R. Obesidad y enfermedad inflamatoria intestinal. Gastroenterol. latinoam 2017; 28: 177-184. Disponible en: http:// gastrolat.org/DOI/PDF/10.0716/gastro- lat2017n3000.04.pdf
Vavricka S, Schoepfer A, Scharl M, Lakatos P, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015; 21: 1982– 1992. Disponible en: https://pubmed.ncbi. nlm.nih.gov/26154136/.
Cano S, Rubio C, Fernández R, Centeno O, Daniel C. Metabolismo mineral óseo en la enfermedad inflamatoria intestinal. Rev Osteoporos Metab Min. 2009; 1: 21–28. Disponible en: https://www.redalyc.org/pdf
/3609/360933648004.pdf.
Bird SP, Tarpenning KM, Marino FE. De-signing resistance training programmes to enhance muscular fitness: a review of the acute programme variables. Sports Med 2005; 35: 841-851. Disponible en: https:// pubmed.ncbi.nlm.nih.gov/16180944/.
Pedersen B, Febbraio M. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012; 8: 457–465. Disponible en: https://pubmed.ncbi. nlm.nih.gov/22473333/.
Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology. Bethesda 2008; 23: 160–170. Disponible en: https://pub- med.ncbi.nlm.nih.gov/18556469/.
Mounier R, Lantier L, Leclerc J, Sotiro-poulos A, Foretz M, Viollet B. Antagonistic control of muscle cell size by AMPK and mTORC1. Cell Cycle 2011; 10: 2640–2646. Disponible en: https://pubmed.ncbi.nlm. nih.gov/21799304/.
Pérez R, Carlos J. Interleukin-10 and Coronary Disease. Rev Española Cardiol 2012; 55: 738-750. Disponible en: https://www. sciencedirect.com/science/article/abs/ pii/S0300893202766931.
Beery RM, Li E, Fishman LN. Impact of pediatric inflammatory bowel disease diagnosis on exercise and sports participation: Patient and parent perspectives. World J Gastroenterol 2019; 25; 4493-4501. Disponible en: https://pubmed.ncbi.nlm.nih. gov/31496627/.
Escribano LI, Rodríguez AS, Centeno G. Etiopathogenic diagnosis protocol of chronic diarrhea. Medicine 2020; 13: 38–44. Disponible en: https://www.medicineonli- ne.es/es-protocolo- diagnostico-etiopatoge- nico-diarrea-cronica-articulo-S0304541220 300056?referer=seccion.
Salvo-Romero E, Alonso-Cotoner C, Pardo-Camacho C, Casado-Bedmar M, Vicario M. Función barrera intestinal y su implicación en enfermedades digestivas. Rev Esp Enferm Dig 2015; 107: 686-696. Disponible en: https://scielo.isciii.es/pdf/diges/ v107n11/es_revision.pdf.
Álvarez J, Fernández-Real JM, Guarner F, Gueimonde M, Rodríguez JM, Saenz M. Gut microbes and health 2021; 44: 519–535. Disponible en: https://www. sciencedirect.com/science/article/pii/ S0210570521000583.
Cronin O, Barton W, Skuse P, Penney N, Garcia-Pérez I, Murphy E. A Prospective metagenomic and metabolomic analysis of the impact of exercise and/or whey protein supplementation on the gut microbiome of sedentary adults. MSystems 2018; 3: 18-44. Disponible en: https://pubmed.ncbi.nlm. nih.gov/29719871/.
Barton W, Penney N, Cronin O, Garcia-Pérez I, Molloy M, Holmes E. The micro-biome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut 2018; 67: 625–633. Disponible en: https://pubmed.ncbi.nlm.nih. gov/28360096/.
Petersen LM, Bautista EJ, Nguyen H, Hanson BM, Chen L, Lek SH. Community characteristics of the gut microbiomes of competitive cyclists. Microbiome 2017; 51: 1–13. Disponible en: https://micro- biomejournal.biomedcentral.com/arti- cles/10.1186/s40168-017-0320-47.
Colmenarez G, Armania E. Calidad de vida en pacientes con enfermedad inflamatoria intestinal. Bol Med Postgrado 2018; 34: 17-23. Disponible en: https://revistas.uclave. org/ index.php/bmp/article/view/2526.
Published
2022-08-23
How to Cite
Fernández-Lázaro , D., Hernández-Burgos, N., Cobreros Mielgo, R., & García-Lázaro, S. (2022). Evaluación de actividad física como coadyuvante terapéutico para pacientes con enfermedad inflamatoria intestinal: una revisión.: Evaluation of physical activity as a therapeutic adjuvant for patients with inflammatory bowel disease: A systematic review. Investigación Clínica, 63(3), 304-322. https://doi.org/10.54817/IC.v63n3a08
Section
Revisiones
